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We report a very rare case report of female diagnosed with primary ma-
lignant melanoma. A 65 years old diabetic elderly postmenopausal female 
presented with a history of intermittent blood spots on undergarments for 
few days. Genital examination revealed a single, tan colored, soft chest-
nut size and polypoidal non ulcerated mass lesion protruding through the 
urethral meatus. Mass biopsy revealed poorly differentiated epithelial ma-
lignancy and immuno-histological analysis revealed positive with HMB 
45 and protein S-100 suggestive of melanoma. Metastatic work up for the 
malignancy was negative. Complete urethrectomy with Mitrofanoff pro-
cedure with inguinal lymph node dissection was performed. Histopatho-
logical examination was suggestive of  malignant melanoma of urethra. 
Here we discuss the clinicopathological features and management option 
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1. Introduction
Primary malignant melanoma of female urethra is very uncommon tumour and constitutes 0.1 - 0.2% of all melanoma [1-5]. Urethral melanoma can be sub 
classified based on its origin type into mucosal melanomas 
or cutaneous melanomas. Urethral melanomas are usually 
under reported clinically  and it inherits grave prognosis 
with poor five year survival rates [6]. Here we present a 
case of an elderly female diagnosed with primary malig-
nant melanoma of urethra in and its surgical management 
at our center along with review the literature.
2. Case Report
A 65 years old diabetic elderly female came  with a his-
tory of intermittent blood spots on undergarments for few 
days. She had no complaints of difficulty in micturition, 
hematuria, flank pain, lithuria. She has attained post 
menopause and had no history of postmenopausal syn-
drome. At primary center she was diagnosed with urethral 
mass and biopsy of mass suggestive of poorly differenti-
ated epithelial malignancy. Immnuohistological analysis 
revealed positive with HMB 45 and protein S-100 which 
were suggestive of melanoma.
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Genital examination revealed a single, tan colored, soft 
chestnut size and polypoidal shape non ulcerated mass 
lesion measuring 2 x 2 x 1 cm protruding through the ure-
thral meatus (Figure 1). Her per vaginal and speculum ex-
amination was normal. Abdominal examination revealed 
no organ enlargement of no  regional lymphadenopathy. 
Figure 1. Urethral malignant melanoma presenting as a 
mass protruding from external urethral meatus on genital 
examination
Abdomen-pelvis contrast enhanced computed tomog-
raphy (CECT) along with MRI T2W saggital sequence 
revealed that single enhancing lesion of 2 x 1.3 cm in ure-
thra with not involvement of periurethral tissue, bladder, 
regional or distant lymphadenopathy.
Initially urethral meatus was difficult to visualize but 
with suprapubic pressure gush of urine flow was seen and 
the glide wire was passed in urethra followed by its serial 
dilatation up to 16 Fr. Cystourethroscopy examination 
revealed polypoidal reddish brown growth involving the 
distal urethra and  urethral meatus. Bladder was unre-
markable. Vaginoscopy showed compression of anterior 
vaginal wall with mass however no any evidence of in-
vasion seen on inspection. Complete urethrectomy with 
formation of continent catheterizable stoma using the ap-
pendix (Mitrofanoff procedure) with inguinal lymph node 
dissection was performed. Mass was removed along with 
the normal appearing surrounding tissue. Frozen section 
of proximal urethral margin and adjacent vaginal mucosa 
were free of tumour.
Gross examination of specimen showed a polypoidal 
solid mass of 2 x 1.8 x 1.5 cm with brownish cut surface 
without any ulceration on surface. Histopathological 
analysis showed loosely cohesive nests of epitheloid cells 
with dusty brown melanin pigments. Malignant cells had 
abundant eosinophilic cytoplasm, large nuclei with promi-
nent nucleoli along with mitotic figures. No lymphovascu-
lar invasion was seen (Figure 2). Immuno-histochemical 
analysis of the malignant cells was positive for protein 
S-100 (Figure 3) and HMB-45 (Figure 4) which are mark-
ers for melanocyte differentiation. 
Figure 2. Microscopic findings of specimen. Large epi-
theloid cells with high N/C ratio.Deposition of melanin 
pigment could not be seen clearly
Figure 3. The immunohistochemical staining findings of 
the surgical specimen. The tumor cells were immunoreac-
tive for S-100 protein
Figure 4. The immunohistochemical staining findings of 
the surgical specimen. The tumor cells were immunoreac-
tive for HMB - 45
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Currently the patient is asymptomatic and is doing 
clean intermittent catherterization through mitrofanoff and 
no recurrence of disease have observed yet.
3. Discussion
Malignant melanoma of urethra was first reported in a 
female by Reed in 1896 [7]. Median  age of presentation is 
68 years [8]. Females are more commonly affected as com-
pared to males (3:2) [9]. Urethral melanoma risk factors are 
not established [10].
Lack of visibility and non-specific symptoms causes 
delay in detection of urethral melanoma. Symptoms may 
include bleeding, urethral mass, pain, lower urinary tract 
symptoms. Clinically, differential diagnosis can be other 
malignant diseases or even benign lesions, including car-
uncle, mucosal prolapse, urethral polyps [11,12].
The diagnosis is confirmed after biopsy from the lesion. 
The metastatic evaluation should be done before surgical 
treatment for this highly invasive neoplasm. An abdom-
inal-pelvic CECT scan provides necessary information 
regarding nodal involvement and metastatic foci. c-KIT 
mutation test is useful as it can dictate  the chemothera-
peutic agents [10].
Metaplasia of squamous and glandular epithelium into 
pigment-producing cells is proposed mechanism for mela-
noma originating from mucosal surface [13].
Like all mucosal melanomas, urethral malignant mela-
noma  has  grave prognosis than its cutaneous melanoma 
counterpart [8]. This is mostly due to significant delay in 
diagnosis because of its inaccessible location and also due 
to its  vertical growth phase in urethral melanomas, lymph 
node metastasis [14]. Median survival in two largest series 
was 16 months [4,5]. Overall survival range was from 2 
months to  191 months. Few case series showed five year 
overall survival in 10% patients [15-19].
Microscopic examination a wide histological spectrum 
like diffuse, nested, fascicular, and storiform growths of 
pleomorphic cells exists in case of urethral malignant mel-
anomas [11]. Thus the role of immunohistochemical markers 
for accurate diagnosis come into existence. In clinical prac-
tice most commonly used melanocytic markers are S-100 
protein and HMB-45. More than 90%  of melanomas react 
with S-100 monoclonal antibody [20]. HMB-45, specific for 
melanocytic neoplasms, is less sensitive than S-100 pro-
tein for identifying melanoma [20]. Positive test with S 100 
protein and subsequent testing with HMB-45 in our case 
confirm definitive diagnosis of malignant melanoma. 
No definitive consensus or guidelines exist for man-
agement of primary malignant urethral melanoma because 
of its extreme rare pathology, however it depends on the 
tumour staging. The definite management of primary 
neoplasm is surgical excision with tumor-free margins 
to achieve control of local disease. Less radical surgical 
approaches are also mentioned in literature which  in-
clude local excision; partial or total urethrectomy, with or 
without inguinal lymphadenectomy, and anterior pelvic 
exenteration, but neither has depicted improved survival 
advantage over other [10]. DiMarco et al have also advo-
cated radical surgeries. They found high rate of urethral 
recurrences (69%) in their cases of partial urethrectomy 
patients was due to inadequate surgical margins. Overall 
disease-specific survival observed was 39% approximate-
ly [5].
Sentinel lymph node (SN) dissection is still controver-
sial in primary urethral melanoma. Though the incidence 
of false-negative SN dissection has gone down, it is still 
not mandatory to perform this procedure in all cases [21]. 
Role of lymphadenectomy as proposed by some au-
thors is not proper established  and is debatable in various 
different case scenario . This procedure, though adds to 
the morbidity of the patient, has failed to improve dis-
ease-specific survival in affected individuals. So, role of 
radical surgery in case of inguinal lymph node involve-
ment is not clear [5]. In our case we performed inguinal 
lymph node dissection in our case.
4. Conclusion 
Urethral melanoma is an uncommon neoplasm with poor 
prognosis. No definitive guidelines for management exists 
till date. All proposed treatment are based upon  case se-
ries/reports. Similar neoplastic diseases also give input for 
its management. Surgical excision with adequate margins 
is gold standard treatment of urethral melanoma. There is 
no basis to do inguinal lymph node dissection in all cas-
es. Adjuvant chemotherapy and immunotherapy can be 
prescribed based upon surgeon preferences as no proper 
guidelines exists in literature.
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